EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China

Shan Gao, Junling Zhuang, Aijun Liu, Dongmei Wang, Wei Wang, Xin Li, Zhihong Wang, Meiyun Fang, Ming Gong, Zhilin Jia, Sun Wu, Zheng Xu und 2 weitere

Cancers · 03.04.2026 · 18 (7) · 1160

DOI: 10.3390/cancers18071160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 03.04.2026. Verfasst von Shan Gao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Beijing Jishuitan Hospital, Capital Medical University, Xicheng District, Beijing 100035, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although multiple pomalidomide-based combinations are active in relapsed and/or refractory multiple myeloma (RRMM), comparative data to guide regimen selection remain limited.

Methods

A total of 230 patients with RRMM from 12 centers in China who received pomalidomide-based regimens were included in this retrospective analysis. Overall response rate (ORR) and progression-free survival (PFS) were compared across regimens incorporating bortezomib or ixazomib (V/IPD), carfilzomib (KPD), or daratumumab (DPD), and multivariable analyses were performed to identify prognostic factors.

Results

The overall ORR was 73.9%, with rates of 63%, 79%, and 85% in the V/IPD (n = 66), KPD (n = 69), and DPD (n = 95) cohorts, respectively. ORR differed significantly between V/IPD and DPD (p = 0.0165), driven by a higher proportion of ≥VGPR in the DPD group. The median PFS for the entire cohort was 17.4 months (95% CI: 13.7–20.1), compared with 15.4 months (95% CI: 12.8–20.5), 14.2 months (95% CI: 6.9–not estimable), and 19.2 months (95% CI: 15.1–24.9) for V/IPD, KPD, and DPD, respectively, without significant differences. In multivariable analysis, DPD was associated with improved ORR (HR 4.83, p < 0.001) but not with PFS. R-ISS stage III predicted inferior response (HR 0.35, p = 0.04), whereas ≥3 prior lines of therapy correlated with shorter PFS (HR 1.77, p = 0.012). Adverse events were predominantly hematologic, with limited grade 3–4 toxicity and no treatment-related mortality.

Conclusions

This multicenter real-world analysis clarifies the relative positioning of commonly used pomalidomide-based regimens in RRMM and underscores the importance of treatment timing and disease stage in optimizing outcomes.

Schlagwörter

Stichwörter der Autor:innen

multicenter analysismultiple myelomapomalidomiderefractoryrelapse

Autor:innen und Institutionen

  • Hematology Department, Beijing Jishuitan Hospital, Capital Medical University, Xicheng District, Beijing 100035, China.
  • Hematology Department, Peking Union Medical College Hospital, Beijing 100023, China.
  • Hematology Department, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
  • Hematology Department, Hengshui People's Hospital, Hengshui 053000, China.
  • Hematology Department, The Affiliated Hospital of Qingdao University, Qingdao 266005, China.
  • Hematology Department, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.

ORCID-Profile: Li Bao

Förderung

  • Beijing Natural Science Foundation

Zitieren

APA

Gao, S., Zhuang, J., Liu, A., Wang, D., Wang, W., Li, X., Wang, Z., Fang, M., Gong, M., Jia, Z., Wu, S., Xu, Z., Wang, G., & Bao, L. (2026). Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China. Cancers, 18(7), 1160. https://doi.org/10.3390/cancers18071160

Vancouver

Gao S, Zhuang J, Liu A, Wang D, Wang W, Li X, et al. Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China. Cancers. 2026;18(7):1160. doi:10.3390/cancers18071160

BibTeX
@article{Gao2026,
  author = {Gao, Shan and Zhuang, Junling and Liu, Aijun and Wang, Dongmei and Wang, Wei and Li, Xin and Wang, Zhihong and Fang, Meiyun and Gong, Ming and Jia, Zhilin and Wu, Sun and Xu, Zheng and Wang, Genjie and Bao, Li},
  title = {Comparative Effectiveness of Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Multicenter Real-World Analysis in China},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {7},
  pages = {1160},
  doi = {10.3390/cancers18071160}
}
Kostenlos starten →